Jove
Visualize
Contact Us

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Glaucoma: Overview01:25

Glaucoma: Overview

1.7K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-minimisation analysis of anti-VEGF therapies in neovascular age-related macular degeneration and diabetic macular oedema in Switzerland.

Journal of medical economics·2025
Same author

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF.

Ophthalmology and therapy·2025
Same author

A Novel Quantitative Assessment Method of Disease Activity in Susac's Syndrome Based on Ultra-Wide Field Imaging.

Current eye research·2021
Same author

A standard set of person-centred outcomes for diabetes mellitus: results of an international and unified approach.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass.

The Journal of hospital infection·2019
Same author

[Unusual congenital iris finding].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2017
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 14, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K

[Long-Term Outcome in Patients with Intravitreal Anti-VEGF Therapy for Exudative AMD].

C A Amstutz1, J Fleischhauer1, S Zweifel1

  • 1Department of Ophthalmology, University Hospital Zurich, Switzerland (Chair: Klara Landau, MD).

Klinische Monatsblatter Fur Augenheilkunde
|April 23, 2015
PubMed
Summary

Intravitreal anti-VEGF therapy stabilizes vision in exudative age-related macular degeneration (AMD) for two years. However, visual acuity declines after three or more years of continued treatment for AMD.

More Related Videos

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.9K
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.5K

Related Experiment Videos

Last Updated: Apr 14, 2026

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.7K
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.9K
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
10:14

Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration

Published on: May 26, 2023

4.5K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Pharmacological Treatments

Context:

  • Exudative age-related macular degeneration (AMD) is a leading cause of vision loss.
  • Intravitreal anti-VEGF therapy has demonstrated efficacy in short-term studies (up to two years).
  • Long-term (3-7 years) outcomes of this treatment for AMD are less understood.

Purpose:

  • To evaluate the long-term (3-7 years) outcomes of intravitreal anti-VEGF therapy in patients with exudative AMD.
  • To assess changes in visual acuity in patients with AMD undergoing extended anti-VEGF treatment.

Summary:

  • A retrospective chart review included patients with exudative AMD treated since 2006.
  • Follow-up periods ranged from 3 to over 7 years, with a mean follow-up of 4.9 years.
  • Visual acuity, measured in ETDRS letters, showed a decline over time, with greater losses at longer follow-up durations (-5.0 at 3-4 years to -19.2 at >7 years).

Impact:

  • Intravitreal anti-VEGF therapy maintains visual acuity in the initial two years of exudative AMD treatment.
  • Sustained visual acuity decline is observed beyond three years despite ongoing anti-VEGF therapy for AMD.
  • These findings highlight the need for further research into long-term management strategies for exudative AMD.